1. Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Number of Hedge Fund Holders — 62
Number of Billionaire Holders — 22
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) leads the ranking by billionaire ownership as its principal development program approaches regulatory review.
On September 17, the company announced submission of a new drug application for azetukalner in focal seizures. The application drew on the Phase 2b X-TOLE and Phase 3 X-TOLE2 studies, which demonstrated statistically significant reductions in monthly seizure frequency compared with placebo.
Azetukalner is a potassium-channel opener designed to reduce excessive neuronal firing. Its development proposition includes once-daily dosing and a mechanism that could complement existing antiseizure medicines.
“We are very pleased to announce completion of the NDA submission for azetukalner in focal seizures in epilepsy,” CEO Ian Mortimer said.
The same announcement contained a material complication. The company voluntarily paused enrollment of new patients in ongoing depression studies following an analysis of neuropsychiatric adverse events. Existing participants remained in the studies, and the company said its epilepsy trials were unaffected.
That distinction is important. Progress in epilepsy supports the lead regulatory opportunity, while the psychiatry pause introduces uncertainty around potential expansion into additional indications. Submission of an application also remains separate from FDA acceptance and approval.
The second-quarter balance sheet contained approximately $1.2 billion in cash, cash equivalents, and marketable securities, with management projecting funding into 2029.
For investors researching neuroscience biotech stocks, the investment case now rests on several separate questions: the epilepsy application’s regulatory outcome, the scope of any eventual label, commercial preparation, and the findings that guide further psychiatric development.
Ranking rationale: Xenon Pharmaceuticals Inc. (NASDAQ: XENE) ranks first with 22 billionaire holders, the highest count in the supplied dataset. Its epilepsy filing and financial resources support its position, while the psychiatry enrollment pause is a material qualification to the broader pipeline outlook.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
